About this trial
Bacterial sexually transmitted infections (STIs) have been steadily increasing in gay, bisexual, and other men who have sex with men (MSM) over the past 2 decades. While that trend started prior to the introduction of human immunodeficiency virus (HIV) pre-exposure prophylaxis (PrEP) in 2012, HIV PrEP has been associated with increases in sexual contacts and decreases in condom use with an resultant acceleration in the increase of bacterial STIs such as gonorrhea, syphilis, and chlamydia.
Eligibility criteria
Qualifiers
Individuals aged > 18 years were eligible for participation if they had a diagnosis of untreated gonorrhea and chlamydia. The untreated status was defined as no antibiotic taken in the previous 28 days to treat gonorrhea and chlamydia.
Disqualifiers
known contraindications or hypersensitivity to doxycycline, pentoxifylline, and nitazoxanide.
Trial design
Treatments tested in this trial
- Doxycyclin
- Pentoxifylline
- Nitazoxanide 500Mg Oral Tablet
Treatment groups
Locations
Sponsors and collaborators
Tanta University
Lead sponsor
Mostafa Mahmoud Bahaa Clinical Pharmacy Department, Horus University, New Damietta, Egypt
Collaborator